In addition, our survival analyses revealed that overexpression of FOXM1 was an independent predictor of increased risk of cancer progression in the subgroup of platinum-resistant patients, regardless of tumor histology and was an independent prognostic factor of worse disease specific survival in non-serous EOC, regardless of patient sensitivity to conventional platinum-based treatment. This evidence concerns the gene FOXM1 and neoplasm.